Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform
Klinische Merkmale, Wirksamkeit und Sicherheitsoutcomes bei chinesischen Patient:innen mit chronischer Nierenerkrankung und Typ-2-Diabetes, die Finerenon begonnen hatten: retrospektive Real-World-Kohortenstudie aus der FOUNTAIN-Plattform
Diabetes, Obesity and Metabolism · 08.11.2026
DOI: 10.1111/dom.71531 ↗Auf einen Blick
Bei 6.537 chinesischen Patient:innen mit CKD und Typ-2-Diabetes ging unter Finerenon das UACR nach 4 Monaten deutlich zurück. eGFR und Serumkalium veränderten sich nur gering.
Fragestellung
Welche Merkmale, Wirksamkeits- und Sicherheitsoutcomes zeigen chinesische Patient:innen mit CKD und T2D nach Beginn von Finerenon in der Routineversorgung?
Methode
Retrospektive Kohortenstudie mit elektronischen Gesundheitsakten aus Tianjin; Einschluss erwachsener Patient:innen mit CKD und T2D, die Finerenon zwischen Januar 2023 und Dezember 2024 begonnen hatten.
Ergebnisse
6.537 Patient:innen. Nach 4 Monaten sank das mediane UACR um 40,7 % (95 %-KI 32,2–49,1), die mittlere eGFR um 3,2 % (95 %-KI 2,4–4,0) und Kalium stieg um 4,6 % (95 %-KI 3,9–5,3). Hyperkaliämie: 4,1 pro 100 Personenjahre.
Schlussfolgerung der Autor:innen
Patient:innen mit CKD und T2D, die Finerenon begonnen hatten, zeigten eine deutliche UACR-Reduktion, einen leichten eGFR-Abfall und waren im Follow-up insgesamt gut verträglich.
Kernaussagen
- UACR nach 4 Monaten um 40,7 % reduziert
- eGFR leicht vermindert, Serumkalium leicht erhöht
- Hyperkaliämie-Inzidenz: 4,1 pro 100 Personenjahre
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.11.2026. Verfasst von Yan Kong und 7 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of En…. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer AG, Bayer.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Finerenone was approved in China in 2022 for adult patients with chronic kidney disease (CKD) associated with Type 2 diabetes (T2D). This study aimed to characterize Chinese patients with CKD and T2D who initiated finerenone in routine clinical practice and to evaluate treatment outcomes. Materials and Methods This retrospective study used electronic health records from Tianjin, China, and included adult patients with CKD and T2D who initiated finerenone between January 2023 and December 2024. Baseline characteristics were summarized. Relative changes in urinary albumin‐to‐creatinine ratio (UACR), estimated glomerular filtration rate (eGFR) and serum potassium were assessed. Recorded hyperkalaemia events were evaluated during follow‐up. Key outcomes were examined in the overall cohort and across subgroups.
Results
A total of 6537 patients were included (66.4% male; mean age 57.6 years). Of these, 97.0% with baseline UACR and eGFR values were categorized as moderate, high, or very high Kidney Disease: Improving Global Outcomes (KDIGO) risk categories. At Month 4, median UACR decreased substantially by 40.7% (95% confidence interval [CI]: 32.2%, 49.1%), the mean eGFR declined slightly by 3.2% (95% CI: 2.4%, 4.0%) and the mean serum potassium increased by 4.6% (95% CI: 3.9%, 5.3%). These trends were generally consistent across subgroups. The incidence rate of hyperkalaemia events was 4.1 per 100 person‐years.
Conclusions
Patients with CKD and T2D who initiated finerenone experienced a substantial reduction in UACR, a slight decrease in eGFR, and were generally well tolerated during follow‐up. These findings reinforce the effectiveness and safety of finerenone in Chinese real‐world clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
- Bayer Healthcare Company Ltd., Beijing, China.
- Bayer AG, Berlin, Germany.
- Real World Solutions, IQVIA Ltd., Shanghai, China.
ORCID-Profile: Huan Wei, Liming Chen
Förderung
- Bayer AG
- Bayer
Zitieren
APA
Kong, Y., Sun, B., Shan, C., Xu, Z., Yang, H., Oberprieler, N. G., Wei, H., & Chen, L. (2026). Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71531
Vancouver
Kong Y, Sun B, Shan C, Xu Z, Yang H, Oberprieler NG, et al. Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71531
BibTeX
@article{Kong2026,
author = {Kong, Yan and Sun, Bei and Shan, Chunyan and Xu, Zhe and Yang, Hui and Oberprieler, Nikolaus G and Wei, Huan and Chen, Liming},
title = {Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71531}
}
EUVIMED